Puma Biotechnology Stock Market Outlook
| PBYI Stock | USD 6.09 0.02 0.33% |
Under 52% of Puma Biotechnology's investor base is interested in shorting. The analysis of the overall investor sentiment regarding Puma Biotechnology suggests that many traders are impartial. The current market sentiment, together with Puma Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use Puma Biotechnology stock news signals to limit their universe of possible portfolio assets.
Investor Comfort Level
Impartial
Panic | Confidence |
Elasticity to Hype and News Sentiment
Puma Biotechnology news sentiment at 54% (mixed) and a heavily bullish crowd reading (100% bullish) together frame how perception and conviction are evolving. When news tone and crowd positioning diverge like this, cross-checking with earnings revisions and price action becomes more important.
News SentimentNeutral | Hype SentimentNeutral | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Puma Biotechnology is 'Strong Hold'. Macroaxis provides Puma Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PBYI positions.
Execute Puma Biotechnology Advice
The Puma recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Puma Biotechnology. Macroaxis does not own or have any residual interests in Puma Biotechnology or other equities on which the buy-or-sell advice is provided.
Time Horizon
Risk Tolerance
 | Strong Hold |  |
Market Performance | Mild | Details | |
Volatility | Moderate | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
For the selected time horizon Puma Biotechnology has a Risk Adjusted Performance of 0.0536, Jensen Alpha of 0.2721, Total Risk Alpha of 0.3761, Sortino Ratio of 0.0483 and Treynor Ratio of 0.1619Our Puma Biotechnology advice works alongside - not in place of - the expert consensus. Macroaxis has no financial interest in this equity or any other asset in this module. To confirm fair pricing, check all Puma Biotechnology fundamentals, including the relationship between the cash and equivalents and target price. Puma Biotechnology has a price to earning of 18.52 X. We recommend you double-check its market performance and bankruptcy risk for the current cycle.
Recent Significant Events and Headlines
Returns Distribution Density
This chart shows how Puma Biotechnology's daily returns have been spread out over time. Most returns cluster near the average, but the tails show how often large gains or losses occur. We use Puma Biotechnology's Value At Risk and Upside Potential to measure both sides of that spread for Puma Biotechnology.
| Mean Return | 0.24 | Value At Risk | -3.92 | Potential Upside | 4.39 | Standard Deviation | 4.30 |
Return Density |
| Distribution |
Good risk management means knowing how likely big price swings are. The chart of Puma Biotechnology's past returns makes it easy to see how often extreme moves have happened. This helps investors compare different investment strategies on a risk-reward basis.
Top Institutional Investors
Institutions hold about 72.85% of Puma Biotechnology shares while insiders own roughly 15.63%. Current market capitalization is about 308.82 Million. At that level, fund flows and index rebalancing drive most of the daily volume. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. Volume spikes around index rebalance dates are worth monitoring given the high institutional share.
| Shares | Charles Schwab Investment Management Inc | 2025-12-31 | 125.4 K |
Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | -22.2M | 3.5M | 7.9M | -15.4M | -39.6M | -37.6M | |
| Free Cash Flow | 20.7M | -22.8M | 14.4M | 38.9M | 41.7M | 43.8M | |
| Other Non Cash Items | 7.1M | 7.0M | 1.5M | -519K | -358K | -340.1K | |
| Capital Expenditures | 1K | 7M | 12.6M | 56K | 71K | 67.5K | |
| Net Income | -29.1M | 2K | 21.6M | 30.3M | 31.1M | 32.7M | |
| End Period Cash Flow | 75.3M | 78.8M | 86.7M | 71.3M | 31.7M | 30.1M | |
| Change To Inventory | -3.7M | 2.6M | -2.6M | -1.6M | 3.2M | 3.4M | |
| Depreciation | 11.3M | 9.8M | 11.5M | 11.5M | 10.9M | 6.4M | |
| Change To Netincome | 66.6M | 37.6M | 39.8M | 18.8M | 21.7M | 20.6M | |
| Change Receivables | -8.1M | 2.4M | -6.0M | -7.8M | -7.0M | -6.7M | |
| Investments | -10.9M | 14.1M | -22.8M | -20.4M | -36.1M | -34.3M |
Key Drivers of Volatility and Market Exposure
Puma Biotechnology is exposed to both systematic and unsystematic risk. Systematic risk reflects broader stock market movements, while company or sector-specific developments represent nonmarket drivers. Diversification may reduce specific risk, but market exposure remains. Beta and standard deviation help quantify volatility. Puma Biotechnology posted a Downside Deviation of 5.39, a Mean Deviation of 2.58, and an Option Implied Volatility of 3.38 for the reported period.
α | Alpha over Dow Jones | 0.27 | |
β | Beta against Dow Jones | 1.44 | |
σ | Overall volatility | 4.47 | |
Ir | Information ratio | 0.06 |
Fundamentals Vs Peers
Comparing Puma Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Puma Biotechnology's direct or indirect competition across all of the common fundamentals between Puma Biotechnology and the related.
| Better Than Average | Worse Than Average | Compare Puma Biotechnology to competition |
| Fundamentals | Puma Biotechnology | Peer Average |
| Return On Equity | 0.28 | -0.31 |
| Return On Asset | 0.11 | -0.14 |
| Profit Margin | 0.14 % | -1.27 % |
| Operating Margin | 0.23 % | -5.51 % |
| Current Valuation | 239.84 M | 16.62 B |
| Shares Outstanding | 50.88 M | 571.82 M |
| Shares Owned By Insiders | 15.63 % | 10.09 % |
| Shares Owned By Institutions | 72.85 % | 39.21 % |
| Number Of Shares Shorted | 3.76 M | 4.71 M |
| Price To Earning | 18.52 X | 28.72 X |
| Price To Book | 2.37 X | 9.51 X |
| Price To Sales | 1.35 X | 11.42 X |
| Revenue | 228.37 M | 9.43 B |
| Gross Profit | 170.21 M | 27.38 B |
| EBITDA | 53.34 M | 3.9 B |
| Net Income | 31.11 M | 570.98 M |
| Cash And Equivalents | 77.96 M | 2.7 B |
| Cash Per Share | 1.71 X | 5.01 X |
| Total Debt | 28.55 M | 5.32 B |
| Debt To Equity | 5.19 % | 48.70 % |
| Current Ratio | 2.04 X | 2.16 X |
| Book Value Per Share | 2.59 X | 1.93 K |
| Cash Flow From Operations | 41.8 M | 971.22 M |
| Short Ratio | 8.26 X | 4.00 X |
| Earnings Per Share | 0.63 X | 3.12 X |
| Price To Earnings To Growth | 0.03 X | 4.89 X |
| Target Price | 5.0 | |
| Number Of Employees | 179 | 18.84 K |
| Beta | 1.27 | -0.15 |
| Market Capitalization | 308.82 M | 19.03 B |
| Total Asset | 216.3 M | 29.47 B |
| Retained Earnings | -1.28 B | 9.33 B |
| Working Capital | 81.43 M | 1.48 B |
Note: Acquisition by Hunt Douglas M of 49394 shares of Puma Biotechnology subject to Rule 16 b-3 [view details]
Market Momentum
Beta of 1.4439 amplifies broad market moves. Strength signals for Puma Biotechnology show whether demand and trading pressure are supporting or weakening the current setup. Puma Biotechnology strength signals are most actionable when combined with support-resistance levels and the implied volatility curve.
Current Target Price Consensus
Puma target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Puma Biotechnology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Hold |
Most Puma analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Puma stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Puma Biotechnology, talking to its executives and customers, or listening to the company's conference calls.
Macroaxis Advice Exposure ValuationPuma Biotechnology Target Price Projection
Puma Biotechnology's current and average target prices are 6.09 and 5.00, respectively. The current price of Puma Biotechnology is the price at which Puma Biotechnology is currently trading. On the other hand, Puma Biotechnology's target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Puma Biotechnology Market Quote on 17th of March 2026
Target Price
Analyst Consensus On Puma Biotechnology Target Price
Puma Biotechnology Analyst Ratings
Puma Biotechnology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Puma Biotechnology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Puma Biotechnology's financials, market performance, and future outlook by experienced professionals. Puma Biotechnology's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Recommendation Framework, Assumptions & Editorial Oversight
The equity advice page for Puma Biotechnology weighs directional signals against your risk tolerance and portfolio goals. It is meant as a decision guide, not a single-line forecast. Puma Biotechnology has a P/E of 18.52, ROE of 27.97%, market cap of 308.82 Million.
Unless otherwise specified, data for Puma Biotechnology is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst inputs may be included when coverage is available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardUse Investing Ideas to Build Portfolios
With 308.82 Million market cap in the Biotechnology industry, Puma Biotechnology works well as a smaller-cap core holding around which broader thematic baskets can be built. Anchoring a Biotechnology theme around Puma Biotechnology at 308.82 Million can be tuned for upside participation or tighter downside control depending on Healthcare outlook.
Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 100 constituents at this time.
Explore the Baby Boomer Prospects Theme as a thematic allocation that can be optimized for return targets or risk constraints.
| View All Next | Launch |
More Resources for Puma Stock Analysis
Reviewing Puma Biotechnology commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Puma Biotechnology's operating context across reporting periods. Key reports that frame Puma Biotechnology Stock are listed below:Puma Biotechnology Analyst Recommendation provides a comparison point for model output and current analyst consensus. For multi-symbol ratings, use Instant Ratings. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Puma Biotechnology P/E of 18.52 alongside ROE at 27.97% frames the starting point - the resources below add portfolio-level context that single-security analysis cannot provide alone. That valuation within Healthcare invites comparison with Biotechnology peers using the tools below to judge whether the multiple is justified. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Quarterly Earnings Growth -0.34 | Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
Market capitalization and book value offer complementary views of Puma Biotechnology - the first driven by investor sentiment, the second by accounting standards. Puma Biotechnology's market capitalization is 308.82 M. A P/B ratio of 2.37 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 239.84 M. Value and price for Puma Biotechnology are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.37, a profit margin of 13.62%, and ROE of 27.97%. The actual Puma Biotechnology transaction price is determined by real-time order flow on the exchange.